The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms ...

Living with depression can feel overwhelming, especially when traditional treatments like medications and talk therapy don’t bring relief. For those struggling with treatment-resistant depression, ...

All FDA warnings are at the end of this fact sheet. Please consult them before taking this medication. What is clonidine and what does it treat? Clonidine is a non-stimulant prescription medication ...

All final determinations of inpatient applicability were made by the investigators and supported by the institution's pharmacy and therapeutics (P&T) committee. Only drugs with inpatient ...